WEREWOLF THERAPEUTICS INC (HOWL)

Company Profile

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is headquartered in Watertown, Massachusetts and currently employs 45 full-time employees. The company went IPO on 2021-04-30. The company is engaged in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712.

Company Info

WEREWOLF THERAPEUTICS INC

200 Talcott Avenue, 2nd Floor

Watertown MASSACHUSETTS 02138

P: 16179520555

CEO: Daniel J. Hicklin

Employees: 45

Website: https://werewolftx.com/